TransMedics Group (TMDX)
(Real Time Quote from BATS)
$89.46 USD
+4.72 (5.57%)
Updated Apr 23, 2024 11:26 AM ET
1-Strong Buy of 5 1
F Value B Growth A Momentum C VGM
TransMedics (TMDX) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$96.67 | $105.00 | $80.00 | 11.74% |
Price Target
Based on short-term price targets offered by six analysts, the average price target for TransMedics comes to $96.67. The forecasts range from a low of $80.00 to a high of $105.00. The average price target represents an increase of 11.74% from the last closing price of $86.51.
Analyst Price Targets (6 )
Broker Rating
TransMedics currently has an average brokerage recommendation (ABR) of 1.29 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by seven brokerage firms. The current ABR compares to an ABR of 1.29 a month ago based on seven recommendations.
Of the seven recommendations deriving the current ABR, six are Strong Buy, representing 85.71% of all recommendations. A month ago, Strong Buy represented 85.71%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 6 | 6 | 6 | 5 | 5 |
Buy | 0 | 0 | 0 | 0 | 0 |
Hold | 1 | 1 | 1 | 1 | 1 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.29 | 1.29 | 1.29 | 1.33 | 1.33 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
11/8/2023 | Canaccord Genuity | Jason R Mills | Strong Buy | Strong Buy |
11/6/2023 | William Blair | Ryan S Daniels | Strong Buy | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.29 |
ABR (Last week) | 1.29 |
# of Recs in ABR | 7 |
Average Target Price | $96.67 |
LT Growth Rate | NA |
Industry | Medical - Instruments |
Industry Rank by ABR | 89 of 252 |
Current Quarter EPS Est: | -0.05 |